Viewing
|Articles|April 30, 2007

FDA denies Lilly appeal

The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME